Sexually Transmitted Diseases (STD) Testing Global Market Report 2025

The sexually transmitted diseases (STD) testing market size has grown strongly in recent years. It will grow from $8.08 billion in 2024 to $8.78 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. Growth during the past years has been driven by increasing urbanization and population density, a growing aging population maintaining active sexual lifestyles, government efforts to promote STD screening, the integration of STD testing into routine health examinations, and greater funding for public health initiatives.

The sexually transmitted diseases (STD) testing market size is expected to see strong growth in the next few years. It will grow to $12.08 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. This anticipated expansion can be credited to the rising global incidence of STDs, enhanced awareness of sexual health issues, the high rate of infections without symptoms, the increasing number of sexually active adolescents and young adults, and a surge in risky sexual behaviors. Key trends forecasted include the rise of rapid and point-of-care testing, the emergence of home-based STD testing kits, progress in molecular diagnostic methods, greater automation and AI integration in diagnostic labs, and improved accuracy and reliability of new testing kits.

The increasing prevalence of HIV is expected to drive the growth of the sexually transmitted diseases (STD) testing market in the upcoming years. HIV attacks and destroys vital white blood cells, weakening the immune system and making the body more susceptible to infections and diseases. The rise in HIV cases is linked to a decline in awareness and prevention efforts, leading to more individuals engaging in risky behaviors such as unprotected sex and fewer people, especially youth, getting tested. This increase in HIV cases has raised public and healthcare awareness, encouraging more people to seek comprehensive testing to detect infections early and prevent further spread. For example, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) in July 2024, approximately 1.3 million people were newly infected with HIV in 2023, nearly three times higher than the 2025 target of fewer than 370,000 cases. Therefore, the growing prevalence of HIV is expected to enhance the demand for STD testing.

Key players in the sexually transmitted diseases (STD) testing market are focusing on the development of advanced solutions, such as syphilis testing kits, to improve accessibility and accuracy. These kits detect the Treponema pallidum bacteria, which causes syphilis, using blood or other bodily fluids, enabling timely diagnosis and treatment. For instance, in August 2023, iHealth Labs Inc., a US medical device company, launched the CheckMeSafe home collection kit for HIV and syphilis testing. This FDA-approved kit allows individuals aged 18 and older to collect blood samples at home for HIV (I, II, P24 antigen) and syphilis testing. Users can send their samples to the lab with a prepaid overnight label and receive confidential, reliable results in as little as two days. The kit offers high accuracy, with sensitivity rates of up to 99.9% for HIV and 99.5% for syphilis. All samples are tested in a CLIA-certified and CAP-accredited laboratory, ensuring compliance with stringent federal and state quality standards through regular inspections.

In December 2023, imaware, a US-based company providing at-home health testing kits, acquired binx health’s at-home consumer testing division. This acquisition will help imaware strengthen its position in the growing home-health testing market and expand its enterprise client base. Meanwhile, binx health will continue to develop and grow its point-of-care molecular diagnostics division, which was not part of the acquisition. Binx health is a US-based provider of sexually transmitted disease (STD) testing solutions.

Major players in the sexually transmitted diseases (std) testing market are F Hoffmann La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson And Co., Hologic Inc., QuidelOrtho Corp., Bio-Rad Laboratories Inc., Cepheid, OraSure Technologies Inc., Meridian Bioscience Inc., Sekisui Diagnostics Ltd., Trinity Biotech Plc, Chembio Diagnostics Inc., Operon SA, Jal Medical Pte. Ltd., Anatolia Geneworks, CLIAwaived Inc., Avecon Healthcare Pvt. Ltd., and AEHEALTH LIMITED.

North America was the largest region in the sexually transmitted diseases (STD) testing market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in sexually transmitted diseases (STD) testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sexually transmitted diseases (STD) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Sexually transmitted disease (STD) testing refers to the medical procedure used to detect infections primarily transmitted through sexual contact. It is essential for early diagnosis, which helps prevent complications and controls the spread of infections through timely treatment and counseling. Regular screening is often advised for sexually active individuals since many infections may not present immediate symptoms but can still be contagious.

The main components of sexually transmitted disease (STD) testing include instruments and services, consumables, and software. Instruments and services comprise the diagnostic devices and support activities utilized in clinical environments for conducting medical tests. These employ both immunoassay and molecular diagnostic technologies and can analyze blood, urine, swabs, semen, and other sample types. This testing is applied for various diseases such as chlamydia, gonorrhea, syphilis, HIV/AIDS, and herpes simplex virus (HSV), serving a range of end users including individuals, healthcare providers, health insurers, government health agencies, NGOs, and community health organizations.

The sexually transmitted diseases (STD) testing market research report is one of a series of new reports that provides sexually transmitted diseases (STD) testing market statistics, including sexually transmitted diseases (STD) testing industry global market size, regional shares, competitors with a sexually transmitted diseases (STD) testing market share, detailed sexually transmitted diseases (STD) testing market segments, market trends and opportunities, and any further data you may need to thrive in the sexually transmitted diseases (STD) testing industry. This sexually transmitted diseases (STD) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sexually transmitted diseases (STD) testing market consists of revenues earned by entities by providing services such as confidential testing, walk-in clinic testing, online test ordering, telehealth consultations, and partner notification services. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted diseases (STD) testing market also includes sales of at-home test kits, multi-infection panel kits, blood collection devices, biohazard specimen bags, and portable sample storage containers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.